October 5, 2015
Theravance Biopharma to Present New Retrospective Clinical Data on VIBATIV(R) (telavancin) Showing Positive Outcomes for Patients With Difficult-to-Treat Infections, Including MRSA, at IDWeek 2015
October 2, 2015
Theravance Biopharma Announces New Employment Inducement Awards
September 21, 2015
Data From New Studies Confirm In Vitro Potency of VIBATIV(R) (Telavancin) Against Gram-Positive Bacteria, Including MRSA
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: